caa a22 4500 606234985 CHVBK 20210128101240.0 cr unu---uuuuu 210128e20150101xx s 000 0 eng 10.1007/s11010-014-2200-6 doi (NATIONALLICENCE)springer-10.1007/s11010-014-2200-6 Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer [Elektronische Daten] [Weibing Zhou, Zhan Wang, Ni Shen, Weiwei Pi, Wuzhong Jiang, Juan Huang, Yuanping Hu, Xiong Li, Lunquan Sun] Anillin (ANLN), an actin-binding protein, is required for cytokinesis. Recently, ANLN has been identified as a biomarker in diverse human cancers; however, the precise role of ANLN in breast cancer remains unclear. In this study, we firstly detected the expression of ANLN in 71 patients with breast cancer by immunohistochemistry, and found ANLN was highly expressed in breast cancer tissues. To evaluate the function of ANLN in breast cancer cells, we employed lentivirus-mediated RNA interference to knock down ANLN expression in two human breast cancer cell lines, MDA-MB-231, and ZR-75-30. Knockdown of ANLN remarkably inhibited the proliferation rate and colony formation ability of both breast cancer cell lines. Moreover, flow cytometry analysis showed that depletion of ANLN in MDA-MB-231 cells blocked the cell cycle progression, with more cells delayed at G2/M phase, due to phosphorylation of Cdc2 and suppression of Cyclin D1. Furthermore, knockdown of ANLN strongly suppressed the migration of breast cancer cells, strengthening the evidence that ANLN could be involved in breast cancer progression. Our results may suggest ANLN as a potential target candidate in breast cancer. Springer Science+Business Media New York, 2014 Anillin nationallicence Breast cancer nationallicence Immunohistochemistry nationallicence RNA interference nationallicence Proliferation nationallicence Zhou Weibing Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Wang Zhan Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Shen Ni Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Pi Weiwei Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Jiang Wuzhong Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Huang Juan Hunan Province Clinic Meditech Research Center for Breast Cancer, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Hu Yuanping Hunan Province Clinic Meditech Research Center for Breast Cancer, Xiangya Hospital, Central South University, Changsha, Hunan, China aut Li Xiong Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008, Changsha, Hunan, China aut Sun Lunquan Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008, Changsha, Hunan, China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 11-19 0300-8177 398:1-2<11 2015 398 11010 https://doi.org/10.1007/s11010-014-2200-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-014-2200-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zhou Weibing Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Wang Zhan Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Shen Ni Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Pi Weiwei Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Jiang Wuzhong Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Huang Juan Hunan Province Clinic Meditech Research Center for Breast Cancer, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Hu Yuanping Hunan Province Clinic Meditech Research Center for Breast Cancer, Xiangya Hospital, Central South University, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Li Xiong Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Sun Lunquan Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008, Changsha, Hunan, China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 11-19 0300-8177 398:1-2<11 2015 398 11010